ADVERTISEMENT
Highlights from the 63rd American Society of Hematology (ASH) Annual Meeting
J Clin Pathways. 2022;8;(1):10-15.
Cost-Effectiveness of Lisocabtagene Maraleucel vs Axicabtagene Ciloleucel for Relapsed or Refractory LBCL
Lisocabtagene maraleucel may be cost-effective vs axicabtagene ciloleucel for relapsed or refractory LBCL from a commercial US payer perspective, according to a study presented at 2021 ASH Annual Meeting.
First-Line Venetoclax Plus Azacitidine vs Intensive Chemotherapy for Patients With AML in the Real-World Setting
In the real-world setting, use of intensive chemotherapy was more common than venetoclax plus azacitidine for patients aged 60-75 years with AML.
Real-World Treatment Patterns and Decision-Making for Patients With MM in the United States
Study results presented at the 2021 ASH Annual Meeting provide valuable real-world data on current treatment patterns and decision-making for patients with MM.
Safety and Cost-Effectiveness of CAR-T Therapy in the Outpatient vs Inpatient Setting
Study findings presented at the 2021 ASH Annual Meeting demonstrate the feasibility and cost-effectiveness of outpatient administration of CAR-T therapy for patients with hematologic malignancies.
Real-World Safety, Efficacy of Belantamab Mafodotin for Relapsed/Refractory MM
In the real-world setting, belantamab mafodotin demonstrates comparable responses and toxicities in patients with MM to those seen in clinical trials.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Current Issue
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Subscribe
Advertisement
Advertisement
Advertisement
Recent Stories
Advertisement